Another small improvement in the FDA regulatory back drop for CYP, with another induced pluripotent stem cell therapy advancing to human trials:
https://musculardystrophynews.com/news/givi-mpc-wins-fda-orphan-drug-status-duchenne-md-treatment/
(the spokesman for the company is incorrect about "we believe that we will be the first [induced pluripotent] stem cell company with a disease-modifying therapy to advance both drugs into human clinical trials" of course, but it demonstrates a continually improving regulatory context)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.005(2.86%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.0¢ | $42.82K | 247.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 141820 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 58088 | 1 |
View Market Depth
| Last trade - 14.00pm 07/08/2025 (20 minute delay) ? |
| CYP (ASX) Chart |